| Literature DB >> 31431987 |
Hart A Goldhar1, Kyle M Walker2, Mohamed Abdelrazek3, Eric C Belanger4, Munir Boodhwani5, Nataliya Milman2,6.
Abstract
OBJECTIVES: Our aim was to evaluate characteristics and prospective adverse aortic outcomes in a cohort of patients with non-infectious histological aortitis.Entities:
Keywords: cardiovascular; giant cell arteritis; other idiopathic inflammatory disorders; temporal arteritis; vasculitis
Year: 2019 PMID: 31431987 PMCID: PMC6649911 DOI: 10.1093/rap/rky051
Source DB: PubMed Journal: Rheumatol Adv Pract ISSN: 2514-1775
Baseline demographic and medical information, aortic parameters and other laboratory results
| Idiopathic aortitis, | Secondary aortitis, | Full cohort | ||
|---|---|---|---|---|
| Female, | 7 (78) | 7 (100) | 14 (88) | 0.48 |
| Age, years | 72.9 | 74.3 | 73.5 | 0.27 |
| Number of cardiovascular risk factors, mean | 2.6 | 1.7 | 2.2 | 0.19 |
| Smoker, | 9 (100) | 3 (43) | 12 (75) | 0.02 |
| Diabetes, | 0 | 1 (14) | 1 (6) | 0.44 |
| Dyslipidaemia, | 3 (33) | 2 (29) | 5 (31) | 1.00 |
| Hypertension, | 6 (67) | 2 (29) | 8 (50) | 0.31 |
| Coronary artery disease, | 2 (22) | 0 | 2 (13) | 0.48 |
| Peripheral vascular disease, | 1 (11) | 1 (14) | 2 (13) | 1.00 |
| Chronic kidney disease, | 0 | 0 | 0 | |
| Baseline medications | ||||
| Aspirin, | 3 (33) | 0 | 3 (19) | 0.21 |
| Other anti-thrombotic, | 0 | 0 | 0 | |
| ACEI or ARB, | 3 (33) | 3 (43) | 6 (35) | 1.00 |
| Statin, | 4 (44) | 3 (43) | 7 (44) | 1.00 |
| β-Blocker, | 5 (56) | 2 (29) | 7 (44) | 0.36 |
| Prednisone, | 1 (11) | 0 | 1 (6) | 1.00 |
| Other immunosuppressant, | 0 | 0 | 0 | |
| Clinical features | ||||
| Aortic dissection, | 0 | 1 (14) | 1 (6) | 0.44 |
| Moderate-to-severe/severe aortic insufficiency, | 5 (56) | 2 (29) | 7 (44) | 0.36 |
| Baseline imaging | ||||
| Aortic root or ascending aorta aneurysm at site of surgery, | 9 (100) | 6 (86) | 15 (94) | 0.44 |
| Maximal diameter, mm, mean ± | 59.3 ± 4.8 | 60.6 ± 6.2 | 59.8 ± 5.1 | |
| Additional vascular lesions, total, | 19 | 10 | 29 | |
| Aortic lesions, total, | 14 | 5 | 19 | |
| Thoracic aorta, total, | 12 | 4 | 16 | |
| Aortic arch ectasia, | 3 | 1 | 4 | |
| Aortic arch aneurysm, | 3 | 0 | 3 | |
| Descending aortic ectasia, | 3 | 3 | 6 | |
| Descending aortic aneurysm, | 3 | 0 | 3 | |
| Abdominal aortic aneurysms, | ||||
| Suprarenal | 1 | 1 | 2 | |
| Infrarenal | 1 | 0 | 1 | |
| Branch lesions, total, | 5 | 5 | 10 | |
| Branch ectasia/aneurysm, | 2 | 4 | 6 | |
| Branch stenosis/occlusion, | 3 | 1 | 4 | |
| Histopathology | ||||
| Giant cells, | 8 (89) | 5 (83) | 13 (81) | 0.55 |
| Lymphoplasmacytic pattern, | 5 (56) | 4 (67) | 9 (56) | 1.00 |
| Medial necrosis, | 8 (89) | 5 (83) | 13 (87) | 0.55 |
| Medial degeneration, | 3 (33) | 3 (50) | 6 (40) | 0.62 |
| Medial fibrosis, | 8 (89) | 4 (67) | 12 (80) | 0.52 |
| Intimal fibrosis, | 6 (67) | 1 (17) | 7 (47) | 0.12 |
| Adventitial fibrosis, | 4 (44) | 3 (50) | 7 (47) | 1.00 |
| Atherosclerosis, | 3 (33) | 3 (50) | 6 (40) | 0.62 |
| Initial inflammatory markers | ||||
| ESR (mm/h) | 21.1 | 16.3 | 18.7 | 0.80 |
| CRP (mg/l) | 6.8 | 19.5 | 12.7 | 0.35 |
Statistical significance was calculated using Fisher’s exact test or the Mann–Whitney U-test; P-values of ≤0.05 were considered significant.
Baseline aortic parameters were recorded from imaging pre-operatively; for those patients without abdominal imaging pre-operatively (n = 10), the first post-operative abdominal imaging was considered baseline (time from surgery to imaging ranged from 1 to 19 months). One patient was initially lost to follow-up and thus had the first abdominal imaging after 84 months.
n in this table refers to total lesions, rather than total patients. Fifteen of 16 patients had surgery for an aneurysm, and one patient had surgery for a dissection.
Baseline values of inflammatory markers were those first recorded ≥90 days post-operatively, to exclude changes related to the post-surgical state. These values were recorded 3–14 months post-operatively. ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers.
Cumulative number of patients with (and total number of) aortic events throughout duration of follow-up
| Idiopathic aortitis ( | Secondary aortitis ( | Total ( | ||
|---|---|---|---|---|
| Median follow-up, years | 4.1 (0.4–7.5) | 3.2 (1.8–6.5) | 3.6 (0.4–7.5) | |
| New thoracic aortic aneurysm, | 3 (3) | 2 (2) | 5 (5) | 1/2/2 |
| New abdominal aortic aneurysm, | 1 (1) | 0 | 1 (1) | 0/0/1 |
| Aortic dissection, | 2 (2) | 1 (1) | 3 (3) | 3/0/0 |
| Aortic rupture, | 0 | 0 | 0 | |
| Other complication requiring intervention, | 1 (1) | 0 | 1 (1) | 0/1/0 |
| New branch ectasia/aneurysm, | 2 (2) | 2 (2) | 4 (4) | 2/1/1 |
| New branch stenosis/occlusion, | 4 (4) | 0 | 4 (4) | 3/0/1 |
| Significant aortic events | 5 (7) | 3 (3) | 8 (10) | 4/3/3 |
The numbers in the Total events by year column demonstrate whether the specified events occurred within the first year post-operatively/between 1 and 2 years post-operatively/or thereafter.
Significant aortic events is a composite outcome corresponding to new thoracic or abdominal aortic aneurysms, dissection, ruptures or other complications requiring aortic intervention.
Number of aortic events stratified by treatment status
| Treatment status | Never treated | Actively treated | Total | |
|---|---|---|---|---|
| Patients (patient-years) | 9 | 6 (19.7) | 3 | 18 |
| Idiopathic aortitis, | 7 (78) | 0 | 2 (22) | 9 |
| Secondary aortitis, | 0 | 6 (86) | 1 (14) | 7 |
| New thoracic aortic aneurysm, | 3 (0.11) | 2 (0.10) | 0 | 5 (0.09) |
| New abdominal aortic aneurysm, | 0 | 0 | 1 (0.09) | 1 (0.02) |
| Aortic dissection, | 2 (0.07) | 1 (0.05) | 0 | 3 (0.05) |
| Further surgical aortic intervention, | 0 | 0 | 1 (0.09) | 1 (0.02) |
| New branch ectasia/aneurysm, | 2 (0.07) | 2 (0.10) | 0 | 4 (0.07) |
| New branch stenosis/occlusion, | 4 (0.14) | 0 | 0 | 4 (0.07) |
| Significant aortic events, | 5 (0.18) | 3 (0.15) | 2 (0.18) | 10 (0.17) |
Remote treatment refers to having ceased immunosuppressive therapy ≥6 months before diagnosis of aortitis.
Two patients had events before initiation of treatment, one of whom later had an event on treatment; they are represented in both groups.
Predictors of severity of damage in aortitis
| Severity of damage | Mild | Moderate | Severe |
|---|---|---|---|
| 5 | 7 | 4 | |
| Median follow-up (years) | 2.7 | 4.2 | 3.8 |
| Female, | 3 (60) | 7 (100) | 4 (100) |
| Mean age, years | 71.6 | 73.7 | 75.5 |
| Idiopathic, | 4 (80) | 3 (43) | 2 (50) |
| Number of cardiovascular risk factors, mean | 2.0 | 2.4 | 2.0 |
| Smoker, | 5 (100) | 4 (57) | 3 (75) |
| Diabetes, | 0 | 1 (14) | 0 |
| Dyslipidaemia, | 2 (40) | 1 (14) | 2 (50) |
| Hypertension, | 3 (60) | 4 (57) | 3 (75) |
| Coronary artery disease, | 0 | 1 (14) | 1 (25) |
| Peripheral vascular disease, | 0 | 1 (14) | 1 (25) |
| Chronic kidney disease, | 0 | 0 | 0 |
| Baseline imaging | |||
| Ascending aneurysm >6.0 cm, | 3 (60) | 3 (50) | 2 (67) |
| Arch aneurysm, | 0 | 1 (14) | 2 (50) |
| Descending aneurysm, | 0 | 1 (14) | 2 (50) |
| Abdominal aneurysm, | 0 | 1 (14) | 1 (25) |
| Branch involvement, | 0 | 2 (29) | 2 (50) |
| Medications | |||
| Aspirin, | 1 (20) | 4 (57) | 2 (50) |
| Other antithrombotic, | 0 | 0 | 0 |
| ACEI or ARB, | 2 (40) | 1 (14) | 1 (25) |
| Statin, | 3 (60) | 4 (57) | 3 (75) |
| β-Blocker, | 2 (40) | 5 (71) | 3 (75) |
| Treatment status | |||
| Never treated, | 4 (80) | 2 (29) | 3 (75) |
| Remotely treated, | 1 (20) | 4 (57) | 1 (25) |
| Actively treated, | 0 | 1 (14) | 0 |
| Inflammatory markers | |||
| Mean ESR >20 (mm/h) | 1 (20) | 2 (29) | 1 (25) |
| Mean CRP >10 (mg/l) | 0 | 1 (14) | 2 (50) |
Baseline aortic diameters were missing for 2 of 16 patients and could not be extrapolated from post-operative imaging because grafts had already been placed.
As recorded at the time of accumulation of that damage.
The mean ESR and CRP for each patient during follow-up was calculated, beginning after 90 days post-operatively, to exclude the post-surgical state. The average number of laboratory measurements per patient was 8.3 (range 2–26), but two patients had none (follow-up period <90 days). ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers.